Skip to main content
. Author manuscript; available in PMC: 2017 Nov 3.
Published in final edited form as: Cell. 2016 Nov 3;167(4):973–984.e12. doi: 10.1016/j.cell.2016.10.025

Figure 4. In Vitro Gal3 Treatment Impairs Insulin Signaling.

Figure 4

(A) Gal3 impairs insulin-stimulated IR tyrosine phosphorylation as shown by IP and IB for IRβ in L6 myocytes and (B) 3T3-L1 adipocytes. (C) Gal3 impairs insulin-stimulated IRS1 tyrosine phosphorylation as shown by ELISA and (D) WB in L6 myocytes. (E) Gal3 impairs insulin-stimulated IRS1 tyrosine phosphorylation as shown by ELISA and (F) Western blot (WB) in 3T3-L1 adipocytes. (G) Gal3 impairs insulin-stimulated p-PDK1 and (H) p-Akt in 3T3-L1 adipocytes. (I) Gal3 decreases insulin-stimulated Glut4 translocation as measured by the by sheet assay and (J) immunofluorescence Glut4 staining ring assay in 3T3-L1 adipocytes. Values are expressed as mean ± SEM. * P<0.05, ** P<0.01. See also Figure S6.